4basebio Statistics
Total Valuation
4basebio has a market cap or net worth of EUR 204.05 million. The enterprise value is 180.75 million.
Market Cap | 204.05M |
Enterprise Value | 180.75M |
Important Dates
The last earnings date was Friday, May 9, 2025.
Earnings Date | May 9, 2025 |
Ex-Dividend Date | n/a |
Share Statistics
Current Share Class | 15.48M |
Shares Outstanding | n/a |
Shares Change (YoY) | +6.47% |
Shares Change (QoQ) | +6.41% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | n/a |
Float | 3.44M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | n/a |
PS Ratio | 180.86 |
PB Ratio | 6.40 |
P/TBV Ratio | 6.67 |
P/FCF Ratio | n/a |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
EV / Earnings | -12.12 |
EV / Sales | 163.11 |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | -13.07 |
Financial Position
The company has a current ratio of 11.30, with a Debt / Equity ratio of 0.58.
Current Ratio | 11.30 |
Quick Ratio | 11.08 |
Debt / Equity | 0.58 |
Debt / EBITDA | n/a |
Debt / FCF | -1.33 |
Interest Coverage | -17.01 |
Financial Efficiency
Return on equity (ROE) is -95.28% and return on invested capital (ROIC) is -31.01%.
Return on Equity (ROE) | -95.28% |
Return on Assets (ROA) | -28.23% |
Return on Invested Capital (ROIC) | -31.01% |
Return on Capital Employed (ROCE) | -30.85% |
Revenue Per Employee | 11,170 |
Profits Per Employee | -147,658 |
Employee Count | 84 |
Asset Turnover | 0.03 |
Inventory Turnover | 0.86 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -21.21% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -21.21% |
50-Day Moving Average | 13.14 |
200-Day Moving Average | 14.57 |
Relative Strength Index (RSI) | 50.45 |
Average Volume (20 Days) | 186 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, 4basebio had revenue of EUR 1.13 million and -14.91 million in losses. Loss per share was -1.14.
Revenue | 1.13M |
Gross Profit | 761,818 |
Operating Income | -15.47M |
Pretax Income | -15.30M |
Net Income | -14.91M |
EBITDA | -14.56M |
EBIT | -15.47M |
Loss Per Share | -1.14 |
Balance Sheet
The company has 42.12 million in cash and 18.40 million in debt, giving a net cash position of 23.72 million.
Cash & Cash Equivalents | 42.12M |
Total Debt | 18.40M |
Net Cash | 23.72M |
Net Cash Per Share | n/a |
Equity (Book Value) | 31.90M |
Book Value Per Share | 2.06 |
Working Capital | 40.66M |
Cash Flow
In the last 12 months, operating cash flow was -12.99 million and capital expenditures -842,836, giving a free cash flow of -13.83 million.
Operating Cash Flow | -12.99M |
Capital Expenditures | -842,836 |
Free Cash Flow | -13.83M |
FCF Per Share | n/a |
Margins
Gross Margin | 67.52% |
Operating Margin | -1,371.17% |
Pretax Margin | -1,356.27% |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
4basebio does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -6.47% |
Shareholder Yield | n/a |
Earnings Yield | -7.31% |
FCF Yield | -6.78% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
Lynch Fair Value | n/a |
Lynch Upside | n/a |
Graham Number | n/a |
Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |
Scores
4basebio has an Altman Z-Score of 3.79.
Altman Z-Score | 3.79 |
Piotroski F-Score | n/a |